Ranganathan S, Williams E, Ganchev P, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Journal of Neurochemistry (Impact Factor: 4.24). 12/2005; 95(5):1461-71. DOI: 10.1111/j.1471-4159.2005.03478.x
Source: PubMed

ABSTRACT Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of motor neurons. We tested the hypothesis that proteomic analysis will identify protein biomarkers that provide insight into disease pathogenesis and are diagnostically useful. To identify ALS specific biomarkers, we compared the proteomic profile of cerebrospinal fluid (CSF) from ALS and control subjects using surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS). We identified 30 mass ion peaks with statistically significant (p < 0.01) differences between control and ALS subjects. Initial analysis with a rule-learning algorithm yielded biomarker panels with diagnostic predictive value as subsequently assessed using an independent set of coded test subjects. Three biomarkers were identified that are either decreased (transthyretin, cystatin C) or increased (carboxy-terminal fragment of neuroendocrine protein 7B2) in ALS CSF. We validated the SELDI-TOF-MS results for transthyretin and cystatin C by immunoblot and immunohistochemistry using commercially available antibodies. These findings identify a panel of CSF protein biomarkers for ALS.

Download full-text


Available from: Robert Bowser, Aug 23, 2015
  • Source
    • "Référence Validation externe Fluide biologique Nombre de composés analysés Modèle multivarié Biomarqueurs (SLA/contrôles) Voies physiopathologiques Pasinetti et al., 2006 [11] Oui LCR 30 Non Cystatine C # Neuroprotection, métabolisme énergétique, plasticité synaptique Protéines 4.8-kDa # VGF# Ranganathan et al., 2005 [12] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Numerous biomarkers studies in ALS used targeted and non-targeted approaches, to help for the diagnosis, the prognosis or to identify new pathophysiological ways. The emerging approaches such as "omics" studies are very promising, but the practical and technical limits do not enable their optimization. Even if some biomarkers such as cystatin C or glutamate are highlighted in ALS, to date, no biomarker is currently used in routine practice. Diffusion-based neuroimaging has emerged as a tool to identify the involvement of the central neuron, but a recent meta-analysis shows a poor sensitivity and specificity. Spinal cord imaging has the advantage of simultaneoulsy investigating both the corticospinal tract and the peripheral motor neurons in the anterior horns of the spinal cord. Its interest to provide biomarkers in ALS is illustrated by recent studies that used a multiparametric approach. The limits of biomarkers studies are principally based on small cohorts, involving a control population who does not allow to assess specificity. The discrepancies between the biomarkers identified in the different studies are based on a strong heterogeneity of the disease and a lack of standardization of the research methodology, including the step of the validation of these molecules in independent cohorts. The perspectives in biomarker research in ALS imply the combination of analytical methods, human abilities and harmonization of the strategies.
    La Presse Médicale 04/2014; 43(5). DOI:10.1016/j.lpm.2014.12.014 · 1.17 Impact Factor
  • Source
    • "Early studies used proteomics to identify oxidatively modified proteins in AD brains, in which creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1 were revealed as specific targets of protein oxidation in AD (Castegna et al., 2002). More recent studies have used proteomics to identify potential biomarkers involved in several neurodegenerative diseases, including ALS (Ranganathan et al., 2005; Ryberg et al., 2010; Zhou et al., 2010), PD (Chen et al., 2011; Lehnert et al., 2012), and AD (Zabel et al., 2012). Indeed, proteomic Additional Supporting Information may be found in the online version of this article. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Understanding the complex biology of the brain requires analyzing its structural and functional complexity at the protein level. The large-scale analysis of the brain proteome, coupled with characterization of central brain proteins, provides insight into fundamental brain processes and processes linked to neurodegenerative diseases. Here we provide a map of the zebrafish brain proteome by using two-dimensional gel electrophoresis (2DE), followed by the identification of 95 brain proteins using mass spectrometry (LC-ESI MS/MS). Our data show extensive phosphorylation of brain proteins but less prominent glycosylation. Furthermore, ∼51% of the identified proteins are predicted to have one or more ubiquitination sites whereas ∼90% are predicted to have one or more SUMOylation sites. Our findings provide a valuable proteome map of the zebrafish brain and associated posttranslational modifications demonstrating that zebrafish proteomic approaches can aid in our understanding of proteins central to important neuronal processes and those associated with neurodegenerative disorders. © 2013 Wiley Periodicals, Inc.
    Journal of Neuroscience Research 01/2014; 92(1). DOI:10.1002/jnr.23297 · 2.73 Impact Factor
  • Source
    • "Two of these studies were based on surface-enhanced laser desorption ionization mass spectrometry profiling of CSF samples (Ranganathan et al. 2005; Pasinetti et al. 2006). Here, a number of protein mass peaks were found to be significantly changed in ALS samples compared with controls including cystatin C, transthyretin , that were decreased as well as neurosecretory protein VGF (Ranganathan et al. 2005; Pasinetti et al. 2006) and secretogranin-5 (7B2) that was found increased, respectively (Ranganathan et al. 2005). Moreover, using a three protein peak model allowed for accurate sample classification at a 95% confidence level (Pasinetti et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a devastating, rapidly progressing disease of the central nervous system that is characterized by motor neuron degeneration in the brain stem and the spinal cord. Matrix assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is an emerging powerful technique that allows for spatially resolved, comprehensive and specific characterization of molecular species in situ. In this study we report for the first time, MALDI imaging-based spatial protein profiling and relative quantification of post mortem human spinal cord samples obtained from ALS patients and controls. In normal spinal cord, protein distribution patterns were well in line with histological features. For example, thymosin beta 4, ubiquitin, histone proteins, acyl CoA binding protein, and macrophage inhibitory factor were predominantly localized to the grey matter. Furthermore, unsupervised statistics revealed a significant reduction of two protein species in ALS grey matter. One of these proteins (m/z 8451) corresponds to an endogenous truncated form of ubiquitin (Ubc 1-76), with both C-terminal glycine residues removed (Ubc-T/Ubc 1-74). This region-specific ubiquitin processing suggests a disease-related change in protease activity. These results highlight the importance of MALDI IMS as a versatile approach to elucidate molecular mechanisms of neurodegenerative diseases. © 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry.
    Journal of Neurochemistry 09/2012; 124(5). DOI:10.1111/jnc.12019 · 4.24 Impact Factor
Show more